SCHEMBL9708098

SCHEMBL9708098

COC(=O)CCn1c(=O)c2c(nc(C3CCCCC3)n2Cc2ccc(-c3ccccc3-c3nnn[nH]3)cc2)n(C)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
MAPK1 P28482 2/20 0.40
POLB P06746 1/20 0.40
BLM P54132 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
KMT2A Q03164 2/20 0.39
P2RX3 P56373 1/20 0.39
PPARG P37231 1/20 0.39
AGTR1 P30556 4/20 0.39
AGTR2 P50052 4/20 0.39
TSHR P16473 3/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9708102 0.94 TSHR (0.44) ALDH1A1NPSR1MAPK1POLBBLM
SCHEMBL9707460 0.91 KMT2A (0.43) ALDH1A1NPSR1MAPK1POLBBLM
SCHEMBL9708064 0.90 DCTPP1 (0.43) NPSR1MAPK1POLBBLMCTDSP1
SCHEMBL9707644 0.90 KMT2A (0.41) ALDH1A1NPSR1MAPK1POLBBLM
SCHEMBL9707874 0.89 TRPC4 (0.43) ALDH1A1KDM4ENPSR1MAPK1POLB
SCHEMBL9707804 0.89 ADORA2A (0.46) NPSR1MAPK1POLBBLMCTDSP1
SCHEMBL9708135 0.88 KMT2A (0.43) NPSR1MAPK1POLBBLMCTDSP1
SCHEMBL9707400 0.88 AGTR1 (0.42) NPSR1MAPK1POLBBLMCTDSP1
SCHEMBL9708212 0.88 KMT2A (0.46) ALDH1A1NPSR1MAPK1POLBBLM
SCHEMBL9708165 0.88 ADORA3 (0.43) NPSR1MAPK1POLBBLMCTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992007852-A1 BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1992-05-14 WO disclosed